

DAFTAR PUSTAKA

1. J. Salazar J, I. Ramírez A, De Hoz R, Salobrar-Garcia E, Rojas P, A. Fernández-Albarral J, et al. Anatomy of the Human Optic Nerve: Structure and Function. *Opt Nerve*. 2019;1–46.
2. Prasad S, Volpe NJ, Balcer LJ. Approach to optic neuropathies: Clinical update. *Neurologist*. 2010;16(1):23–34.
3. Rigi M, Almarzouqi SJ, Morgan ML, Lee AG. Papilledema: Epidemiology, etiology, and clinical management. *Eye Brain*. 2015;7:47–57.
4. Crum OM, Kilgore KP, Sharma R, Lee MS, Spiegel MR, McClelland CM, et al. Etiology of Papilledema in Patients in the Eye Clinic Setting Key Points. *JAMA Netw Open* [Internet]. 2020;3(6):206625. Available from: <https://jamanetwork.com/>
5. K D. *Physiology of Eye and Vision*. 4th ed. *Essentials of Ophthalmology*. India: New Age International (P) Ltd., Publishers; 2015. 15–15 p.
6. Papilledema (Optic Disc Swelling): Symptoms, Causes, Treatment [Internet]. [cited 2022 Jan 8]. Available from: <https://www.webmd.com/eye-health/papilledema-optic-disc-swelling>
7. Devanand YO, Wahyuni DA, Zen NF. Karakteristik Klinis Kelainan Mata pada Pasien dengan Massa Intrakranial di RSUP Dr. Moh. Hoesin Palembang Periode 1 Januari 2013-31 Desember 2015. *Maj Kedokt Sriwij.* 2017;49(2):100–9.
8. Hemanandini M, Sumathi P, Kochami PA. Intracranial Tumors : An Ophthalmic Perspective. 2016;15(6):60–2.
9. Corcoran AC. IN MALIGNANT HYPERTENSION. 2015;

10. American Academy of Ophthalmology. Basic and Clinical Science Course Complete Set. Update on. J., Herbert Ingraham M, K, Darin. Bowers M, editors. San Fransisco;
11. Remington LA. Visual System. Clinical Anatomy and Physiology of the Visual System. 2012. 1–9 p.
12. Huff T, Tadi P, Varacallo M. Neuroanatomy, Cerebrospinal Fluid. StatPearls [Internet]. 2021 Oct 21 [cited 2022 Jan 27]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470578/>
13. Telano LN, Baker S. Physiology, Cerebral Spinal Fluid (CSF) [Internet]. StatPearls. StatPearls Publishing; 2018 [cited 2022 Jan 27]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK519007/>
14. Guyton AC, Hall JE. Text Book of Medical Physiology. 11th ed. Schmitt W, Gruliow R, editors. Physiology. Pennsylvania: Saunders; 2005.
15. Killer HE. Production and circulation of cerebrospinal fluid with respect to the subarachnoid space of the optic nerve. J Glaucoma [Internet]. 2013 Jun [cited 2022 Jan 27];22 Suppl 5(5 SUPPL.1). Available from: <https://pubmed.ncbi.nlm.nih.gov/23733131/>
16. Mathieu E, Gupta N, Ahari A, Zhou X, Hanna J, Yücel YH. Evidence for Cerebrospinal Fluid Entry Into the Optic Nerve via a Glymphatic Pathway. Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4784–91.
17. Wilson MH. Monro-Kellie 2.0: The dynamic vascular and venous pathophysiological components of intracranial pressure. J Cereb Blood Flow Metab [Internet]. 2016 Aug 1 [cited 2022 Jan 28];36(8):1338–50. Available from:

<https://journals.sagepub.com/doi/10.1177/0271678X16648711>

18. Keegan MT, Wijdicks EFM. Increased Intracranial Pressure. *Neurol Disord Course Treat Second Ed* [Internet]. 2021 Sep 29 [cited 2022 Jan 28];749–63. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482119/>
19. Increased Intracranial Pressure (ICP) Headache | Johns Hopkins Medicine [Internet]. [cited 2022 Jan 28]. Available from: <https://www.hopkinsmedicine.org/health/conditions-and-diseases/headache/increased-intracranial-pressure-icp-headache>
20. Edmond J. FitzGibbon MD, Danah Albreiki MF. Papilledema - American Academy of Ophthalmology [Internet]. 2021 [cited 2022 Feb 6]. Available from: <https://eyewiki.aao.org/Papilledema>
21. Passi N, Degnan AJ, Levy LM. MR imaging of papilledema and visual pathways: Effects of increased intracranial pressure and pathophysiologic mechanisms. *Am J Neuroradiol*. 2013;34(5):919–24.
22. Chen JJ, Bhatti MT. Papilledema. *Int Ophthalmol Clin*. 2019;59(3):3–22.
23. Moran CORE | Disc Edema [Internet]. [cited 2022 Feb 9]. Available from: <http://morancore.utah.edu/basic-ophthalmology-review/disc-edema/>
24. Definition of brain tumor - NCI Dictionary of Cancer Terms - National Cancer Institute [Internet]. [cited 2022 Feb 28]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/brain-tumor>
25. Brain Tumors - Classifications, Symptoms, Diagnosis and Treatments [Internet]. [cited 2022 Feb 28]. Available from: <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and->

Treatments/Brain-Tumors

26. Aman RA, Soernarya MF, Andriani R, Munandar A, Tadjoeidin H, Susanto E, et al. Brain Tumor Management Guideline. Natl Cancer Combat Comm [Internet]. 2016;1–79. Available from:
<http://kanker.kemkes.go.id/guidelines.php?id=5>
27. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin.* 2020 Jan;70(1):7–30.
28. Brain Tumor: Statistics | Cancer.Net [Internet]. [cited 2022 Feb 28]. Available from: <https://www.cancer.net/cancer-types/brain-tumor/statistics>
29. Brain Cancer & Brain Tumor: Symptoms, Causes & Treatments [Internet]. [cited 2022 Mar 1]. Available from:
<https://my.clevelandclinic.org/health/diseases/6149-brain-cancer-brain-tumor>
30. Siegel RL, Al. KDM et, CA. Brain Tumor | American Brain Tumor Association [Internet]. [cited 2022 Feb 28]. Available from:
https://www.abta.org/about-brain-tumors/brain-tumor-education/?gclid=CjwKCAiAgvKQBhBbEiwAaPQw3IqRhVWGjN5TE4XYwCc3Y6cWHagYQmOGuai3Bv-ZJRT0aajMxLJrAxoC9NYQAvD_BwE
31. Gupta A, Dwivedi T. A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016. *J Neurosci Rural Pract* [Internet]. 2017 Oct 1 [cited 2022 Mar 4];8(4):629. Available from: </pmc/articles/PMC5709890/>
32. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of

- Tumors of the Central Nervous System: a summary. *Acta Neuropathol.* 2016;131(6):803–20.
33. Alther B, Mylius V, Weller M, Gantenbein A. From first symptoms to diagnosis: Initial clinical presentation of primary brain tumors. *Clin Transl Neurosci.* 2020;4(2):2514183X2096836.
 34. Signs & Symptoms | SEER Training [Internet]. [cited 2022 Mar 4]. Available from:
<https://training.seer.cancer.gov/brain/tumors/symptoms.html>
 35. Antonia Kartika M, Rahmani S. Papilledema as an Isolated Finding of Intracranial Tumor. 2022.
 36. McFaline-Figueroa JR, Lee EQ. Brain Tumors. *Am J Med* [Internet]. 2018;131(8):874–82. Available from:
<https://doi.org/10.1016/j.amjmed.2017.12.039>
 37. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults a report of the American College of Cardiology/American Heart Association Task Force on Clinical practice guidelines. *Hypertension.* 2018 Jun 1;71(6):E13–115.
 38. Sirisha G, Swetha S, Chowdary NL. Evaluation of Etiological Factors and Visual Field Defects in Patients with Papilloedema. 2016 [cited 2022 Nov 6]; Available from: www.ijcmr.com
 39. Blitshteyn S, Crook JE, Jaeckle KA. Is there an association between meningioma and hormone replacement therapy? *J Clin Oncol.*

- 2008;26(2):279–82.
40. Lusic EA, Scheithauer BW, Yachnis AT, Fischer BR, Chicoine MR, Paulus W, et al. Meningiomas in pregnancy: A clinicopathologic study of 17 cases. *Neurosurgery*. 2012;71(5):951–61.
 41. Heaney AP, Fernando M, Melmed S. Functional role of estrogen in pituitary tumor pathogenesis. 2001;1–8.
 42. Pituitary Adenomas: Definition, Symptoms & Treatment [Internet]. [cited 2022 Nov 14]. Available from: <https://my.clevelandclinic.org/health/diseases/15328-pituitary-adenomas>
 43. Sun T, Plutynski A, Ward S, Rubin JB. An integrative view on sex differences in brain tumors. *Cell Mol Life Sci* [Internet]. 2015 Sep 12 [cited 2022 Nov 7];72(17):3323. Available from: [/pmc/articles/PMC4531141/](https://pubmed.ncbi.nlm.nih.gov/2611141/)
 44. Hong H, Wang Q, Li J, Liu H, Meng X, Zhang H. Aging, Cancer and Immunity. *J Cancer* [Internet]. 2019 [cited 2022 Nov 7];10(13):3021–7. Available from: <http://www.jcancer.org>
 45. Ogawa T, Sawada N, Iwasaki M. Annals of Epidemiology Original article Body mass index and height in relation to brain tumor risk in a Japanese population. *Ann Epidemiol* [Internet]. 2020;51:1–6. Available from: <https://doi.org/10.1016/j.annepidem.2020.06.001>
 46. Andrews LE, Liu GT, Ko MW. Idiopathic intracranial hypertension and obesity. *Horm Res Paediatr*. 2014;81(4):217–25.
 47. Hannerz J, Ericson K. The relationship between idiopathic intracranial hypertension and obesity. *Headache*. 2009;49(2):178–84.
 48. Metzger AK, Segal N, Olson DW, Figueroa SA, Sadaka FG, Krause CA, et

- al. Intrathoracic pressure regulation therapy applied to ventilated patients for treatment of compromised cerebral perfusion from brain injury. [cited 2022 Nov 8]; Available from: <https://doi.org/10.1186/s13256-018-1720-1>
49. Malbrain MLNG, Pelosi P, Quintel M. Effect of intra-abdominal pressure on respiratory mechanics. *Acta Clin Belg* [Internet]. 2007;(1):78–88. Available from: <http://www.scopus.com/inward/record.url?eid=2-s2.0-34047147031&partnerID=MN8TOARS>
50. Edlinger M, Strohmaier S, Jonsson H, Bjørge T, Manjer J, Borena WT, et al. Blood pressure and other metabolic syndrome factors and risk of brain tumour in the large population-based Me-Can cohort study. *J Hypertens*. 2012;30(2):290–6.
51. Pituitary Gland Tumor: Symptoms and Signs | Cancer.Net [Internet]. [cited 2022 Nov 15]. Available from: <https://www.cancer.net/cancer-types/pituitary-gland-tumor/symptoms-and-signs>
52. Palmer R, Nyssens AF, White JC. Severe Hypertension with Papilledema Simulating Brain Tumor. *N Engl J Med* [Internet]. 1994;330(23):1639–44. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7993409>
53. Tajunisah I, Patel DK. Malignant hypertension with papilledema. *J Emerg Med* [Internet]. 2013;44(1):164–5. Available from: <http://dx.doi.org/10.1016/j.jemermed.2011.05.042>
54. Rosenberg GA. Cerebrospinal Fluid: Formation, Absorption, Markers, and Relationship to Blood-Brain Barrier. Formation, Absorption, Markers, and Relationship to Blood-Brain Barrier. *Prim Cerebrovasc Dis* Second Ed. 2017;342(6156):25–31.

55. Eggenberger ER, Pula JH. Neuro-ophthalmology in Medicine [Internet]. Aminoff's Neurology and General Medicine: Fifth Edition. Elsevier Inc.; 2014. 479–502 p. Available from: <http://dx.doi.org/10.1016/B978-0-12-407710-2.00024-2>
56. Azmeh A. Neuro-Ophthalmology Findings in Pituitary Disease (Review of Literature). *Pituit Dis.* 2019;
57. Lin AL, Avila EK. Neurologic Emergencies in the Patients with Cancer: Diagnosis and Management. *J Intensive Care Med.* 2017;32(2):99–115.
58. Berkenstock M, Keisling M, Liu J, Pascasio JM. Ophthalmology and Clinical Research : Supratentorial Anaplastic Ependymoma with Bilateral Papilledema. 2015;2–5.
59. Kaye AH, Briggs RJS, Morokoff AP. Acoustic neurinoma (vestibular schwannoma) [Internet]. Third Edit. *Brain Tumors: An Encyclopedic Approach, Expert Consult - Online and Print.* Elsevier Ltd; 2011. 518–569 p. Available from: <http://dx.doi.org/10.1016/B978-0-443-06967-3.00028-4>
60. Biousse V, Szewka A, Newman NJ. Papilledema. *Encycl Neurol Sci.* 2014;3(c):783–5.
61. Sorribes IC, Moore MNJ, Byrne HM, Jain H V. A Biomechanical Model of Tumor-Induced Intracranial Pressure and Edema in Brain Tissue. 2019; Available from: <https://doi.org/10.1016/j.bpj.2019.02.030>

LAMPIRAN

Lampiran 1 Surat Persetujuan Etik Penelitian



REKOMENDASI PERSETUJUAN ETIK

Nomor : 447/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 22 Agustus 2022


Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22070343	No Sponsor	
Peneliti Utama	Hani Septian Farahdella	Sponsor	
Judul Peneliti	KARAKTERISTIK PAPILLEDEMA PADA PASIEN TUMOR INTRAKRANIAL DI RSUP DR. WAHIDIN SUDIROHUSODO PERIODE JANUARI 2021 – DESEMBER 2021		
No Versi Protokol	1	Tanggal Versi	6 Juli 2022
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 22 Agustus 2022 sampai 22 Agustus 2023	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2 Surat Izin Penelitian



Nomor : UM.01.05/2.1/13319/2022
Hal : Izin Penelitian

05 Oktober 2022

Yth. KPSS. Kedokteran Fakultas Kedokteran
Universitas Hasanuddin

Sehubungan dengan surat saudara nomor **14299/UN4.6.8/PT.01.04/2022** tertanggal **28 Juni 2022**, hal **Permohonan Izin Penelitian**, dapat kami fasilitasi dan memberikan izin pelaksanaan penelitian kepada:

Nama : **Hani Septia Farahdella**
NIM : **C011191084**
Prog. Pend. : **Sarjana Kedokteran**
No. HP : **081319214076**
Judul : **Karakteristik Papilledema pada Pasien Tumor Intrakranial Di RSUP. Dr. Wahidin Sudirohusodo Periode Januari 2021 - Desember 2021**
Jangka Waktu : **Tiga Bulan Setelah Surat ini di Keluarkan**
Lokasi : **Inst. Rekam Medik;**

1. Sesuai dengan peraturan dan ketentuan penelitian yang berlaku di lingkup RSUP Dr Wahidin Sudirohusodo
2. Sebelum meneliti, peneliti wajib melapor kepada Pengawas Penelitian di masing-masing unit yang menjadi lokasi penelitian
3. Pelaksanaan penelitian tidak mengganggu proses pelayanan terhadap pasien
4. Pemeriksaan penunjang, BHP dan lain-lain yang digunakan dalam penelitian, menjadi tanggung jawab peneliti, tidak dibebankan kepada pasien ataupun RS
5. Peneliti melaporkan proses penelitian secara periodik serta hasil penelitian di akhir waktu penelitian
6. Mencantumkan nama RSUP Dr Wahidin Sudirohusodo sebagai afiliasi institusi dalam naskah dan publikasi penelitian
7. Surat Keterangan Selesai Penelitian menjadi salah satu syarat untuk mengikuti Seminar Hasil Penelitian
8. Bukti Penyerahan Skripsi/Thesis/Disertasi ke RSUP Dr Wahidin Sudirohusodo menjadi syarat penyelesaian studi.


Mohon dapat dipastikan agar ketentuan tersebut dipenuhi peneliti sebelum menyelesaikan studi di institusi saudara. Atas perhatian dan Kerjasama yang baik, diucapkan terima kasih.

a.n. Direktur Utama
Pjt. Direktur Sumber Daya Manusia,
Pendidikan dan Penelitian,



Ridhayani B, SKM, M.Kes
NIP197110271997032001

Tembusan:
1. Kepala Instalasi Rekam Medik

Lampiran 3 Curriculum Vitae

Nama : Hani Septia Farahdella
 NIM : C011191084
 Tempat, Tanggal Lahir : Jakarta, 18 September 2001
 Jenis Kelamin : Perempuan
 No. Telp : 081319214076
 Fakultas/Angkatan : Kedokteran/2019
 Email : haniseptia1809@gmail.com

Riwayat Pendidikan

Jenjang Pendidikan	Nama Sekolah	Tahun
Sekolah Dasar	Jakarta Islamic School	2007 - 2013
Sekolah Menengah Pertama	SMPN 109 Jakarta	2013 - 2016
Sekolah Menengah Atas	SMAN 26 Jakarta	2016 - 2019
Perguruan Tinggi	Universitas Hasanuddin	2019 - sekarang

Lampiran 4 Karakteristik Papilledema pada Pasien Tumor Intrakranial Juni 2018 – Desember 2022

NO	No.RM	Tahun	Jenis Kelamin	Umur (tahun)	IMT (Kg/M ²)	TD	Lapang Pandangan	Tumor	Ukuran (cm)
1	862249	2018	perempuan	63	26.78	100/51	ODS: sulit dievaluasi	massa supracellar dextra	3.3 x 4.4
2	896381	2019	perempuan	34	24.73	120/80	ODS: sulit dievaluasi	massa regio frontal	4.63 x 4.8 x 4.17
3	875045	2019	perempuan	34	26.49	138/75	ODS: dalam batas normal	meningioma frontotemporal dextra	1.5 x 1.7 x 1.6
4	896317	2019	laki - laki	30	21.77	130/80	penglihatan ganda	massa pineal body	1.33 x 1.24 x 1.23
5	919336	2020	perempuan	39	16.44	118/80	OD: defek superotemporal OS: sulit dinilai	massa suprasellar	3.2 x 3.2 x 2.8
6	953610	2021	perempuan	45	32.05	145/90	OD: tidak dapat dievaluasi OS: hemianopsia temporal	massa extra axial regio frontalis dextra	4.3 x 4.1 x 3.5
7	947475	2021	perempuan	34	26.84	118/80	ODS: dalam batas normal	massa extra axial regio temporo occipitalis dextra	6.18 x 4.46 x 5.67
8	949294	2021	perempuan	46	27.34	120/89	ODS: sulit dievaluasi	multiple massa extra-axial parietal	5.44 x 6.73 x 7.54
9	938898	2021	perempuan	54	24.99	138/80	ODS: dalam batas normal	massa supracellar	1.4 x 1.3 x 0.6
10	949619	2021	laki - laki	40	23.44	138/80	ODS: sulit dievaluasi	massa intraventrikel	4.36 x 6.96 x 5.9
11	920541	2021	perempuan	51	26.56	136/87	OD: sulit dievaluasi OS: dalam batas normal	massa sella	2.9 x 2.1 x 3.1

12	930108	2021	perempuan	44	21.33	130/79	ODS sulit dievaluasi	massa frontalis sinistra	3.5 x 4.7 x 3.7
13	983259	2022	perempuan	52	22.67	110/79	ODS: sulit dievaluasi	massa regio temporal sinistra	5.25 x 5.85
14	967363	2022	perempuan	41	28.76	120/80	OD: sulit dievaluasi OS: dalam batas normal	massa temporofrontal dextra	5.4 x 5.7 x 5.84
15	759024	2022	perempuan	58	24.61	140/90	OD: dbn OS: superior menurun	massa supracellar	0.84 x 0.94 x 0.69
16	979550	2022	laki - laki	24	20.7	110/65	ODS: sulit dievaluasi	massa extra-axial falx cerebri posterior	7.8 x 5.9 x 5.9